Published in AIDS Weekly, February 3rd, 1997
The patients, who had a median CD4 count of 15 cells/(mu)L when the study began, had a median CD4 increase of 86 cells/(mu)L after 24 weeks of the three-drug treatment.
The aggressive treatment used Merck's indinavir (IDV) protease inhibitor and two nucleoside analog reverse transcriptase inhibitors (NARTIs), zidovudine (AZT) and lamivudine (3TC). Glaxo Wellcome manufactures AZT and 3TC.
The findings were announced by Martin Hirsch of Massachusetts General Hospital at the Fourth Conference on Retroviruses...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.